NCT07607288Enrolling by invitation
Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.
Clinical Study on the Correlation Between Plasma Concentrations of Antituberculosis Drugs and Treatment Efficacy/Safety.
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to investigate the correlation between anti-tuberculosis drug concentration monitoring and treatment efficacy and safety through analytical studies.The main questions it aims to answer include: Guidance for individualized dosage adjustment of anti-tuberculosis drugs; Guidance on medication challenges for special populations and patients with comorbidities;Address the dose optimization issue for refractory tuberculosis.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 2215 (estimated)
- First submitted
- 13 May 2026
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Beijing Chest Hospital
- Diseases
- Tuberculosis
- NCT number
- NCT07607288
What you commit to
- Study type: Observational
- Planned participants: 2215
- From 1 Jan 2021 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent chronic liver diseases such as chronic hepatitis B, hepatitis C, or alcoholic liver disease;
- Concurrent severe underlying cardiac conditions (e.g.,congenital heart disease, cardiomyopathy, severe arrhythmias);
- Concurrent use of multiple medications that may affect cardiac function;
Other illness
- Human immunodeficiency virus (HIV) co-infection;
Lab values
- Baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels\>2 times the upper limit of normal;
Other
- Women who are pregnant or breastfeeding.
Who the study is looking for
- Patients with tuberculosis confirmed by bacteriological or pathological diagnosis;
- Those who have received standardized anti-tuberculosis treatment regimens;
- Patients with complete clinical records and completed follow-up for at least one treatment course.
Age in the registry: 5 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.